Shares of ARGENX SE-ADR (NASDAQ:ARGX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price objective of $30.33 for the company, according to Zacks. Zacks has also assigned ARGENX SE-ADR an industry rank of 167 out of 265 based on the ratings given to related companies.

Several analysts recently issued reports on the stock. Cowen and Company reaffirmed a “buy” rating on shares of ARGENX SE-ADR in a research note on Thursday, August 24th. Zacks Investment Research raised shares of ARGENX SE-ADR from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research note on Tuesday.

Shares of ARGENX SE-ADR (NASDAQ ARGX) opened at $23.21 on Friday.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC purchased a new stake in ARGENX SE-ADR during the 2nd quarter valued at about $15,990,000. VHCP Management II LLC purchased a new stake in ARGENX SE-ADR during the 2nd quarter valued at about $13,615,000. Pictet Asset Management Ltd. purchased a new stake in ARGENX SE-ADR during the 3rd quarter valued at about $11,812,000. Federated Investors Inc. PA purchased a new stake in ARGENX SE-ADR during the 2nd quarter valued at about $9,545,000. Finally, Franklin Resources Inc. purchased a new stake in ARGENX SE-ADR during the 2nd quarter valued at about $7,424,000. 22.74% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “ARGENX SE-ADR (ARGX) Given Consensus Recommendation of “Strong Buy” by Brokerages” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/04/argenx-se-adr-argx-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on ARGENX SE-ADR (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with MarketBeat.com's FREE daily email newsletter.